Emergent Biosolutions PE Ratio 2010-2023 | EBS
Current and historical p/e ratio for Emergent Biosolutions (EBS) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Emergent Biosolutions PE ratio as of June 05, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Emergent Biosolutions PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-06-05 |
7.91 |
|
0.00 |
| 2022-12-31 |
11.81 |
$-4.48 |
0.00 |
| 2022-09-30 |
20.99 |
$0.78 |
26.91 |
| 2022-06-30 |
31.04 |
$-1.35 |
0.00 |
| 2022-03-31 |
41.06 |
$-0.83 |
0.00 |
| 2021-12-31 |
43.47 |
$-0.67 |
0.00 |
| 2023-03-31 |
10.36 |
$-2.89 |
0.00 |
| 2021-09-30 |
50.07 |
$4.20 |
11.92 |
| 2021-06-30 |
62.99 |
$5.54 |
11.37 |
| 2021-03-31 |
92.91 |
$7.18 |
12.94 |
| 2020-12-31 |
89.60 |
$5.66 |
15.83 |
| 2020-09-30 |
103.33 |
$3.11 |
33.23 |
| 2020-06-30 |
79.08 |
$3.21 |
24.64 |
| 2020-03-31 |
57.86 |
$1.30 |
44.51 |
| 2019-12-31 |
53.95 |
$1.03 |
52.38 |
| 2019-09-30 |
52.28 |
$0.07 |
746.86 |
| 2019-06-30 |
48.31 |
$-0.35 |
0.00 |
| 2019-03-31 |
50.52 |
$0.81 |
62.37 |
| 2018-12-31 |
59.28 |
$1.22 |
48.59 |
| 2018-09-30 |
65.83 |
$1.96 |
33.59 |
| 2018-06-30 |
50.49 |
$2.23 |
22.64 |
| 2018-03-31 |
52.65 |
$1.36 |
38.71 |
| 2017-12-31 |
46.47 |
$1.69 |
27.50 |
| 2017-09-30 |
40.45 |
$1.69 |
23.93 |
| 2017-06-30 |
33.91 |
$1.46 |
23.23 |
| 2017-03-31 |
29.04 |
$1.08 |
26.89 |
| 2016-12-31 |
32.84 |
$0.95 |
34.57 |
| 2016-09-30 |
31.53 |
$0.99 |
31.85 |
| 2016-06-30 |
26.35 |
$1.33 |
19.81 |
| 2016-03-31 |
34.06 |
$1.92 |
17.74 |
| 2015-12-31 |
37.49 |
$1.25 |
29.99 |
| 2015-09-30 |
26.70 |
$1.20 |
22.25 |
| 2015-06-30 |
30.88 |
$0.90 |
34.31 |
| 2015-03-31 |
26.95 |
$0.71 |
37.96 |
| 2014-12-31 |
25.52 |
$0.73 |
34.95 |
| 2014-09-30 |
19.97 |
$0.48 |
41.60 |
| 2014-06-30 |
21.05 |
$0.35 |
60.13 |
| 2014-03-31 |
23.68 |
$0.51 |
46.43 |
| 2013-12-31 |
21.54 |
$0.84 |
25.65 |
| 2013-09-30 |
17.85 |
$0.87 |
20.52 |
| 2013-06-30 |
13.51 |
$0.69 |
19.58 |
| 2013-03-31 |
13.10 |
$0.61 |
21.47 |
| 2012-12-31 |
15.03 |
$0.64 |
23.48 |
| 2012-09-30 |
13.32 |
$0.98 |
13.59 |
| 2012-06-30 |
14.20 |
$0.84 |
16.90 |
| 2012-03-31 |
14.99 |
$1.02 |
14.70 |
| 2011-12-31 |
15.78 |
$0.60 |
26.30 |
| 2011-09-30 |
14.46 |
$0.58 |
24.93 |
| 2011-06-30 |
21.13 |
$0.95 |
22.24 |
| 2011-03-31 |
22.64 |
$0.87 |
26.02 |
| 2010-12-31 |
21.98 |
$1.56 |
14.09 |
| 2010-09-30 |
16.17 |
$0.93 |
17.39 |
| 2010-06-30 |
15.31 |
$0.55 |
27.84 |
| 2010-03-31 |
15.73 |
$0.72 |
21.85 |
| 2009-12-31 |
12.73 |
$0.99 |
12.86 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.416B |
$1.121B |
|
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
|
